Wolverine Trading’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$227K Buy
+28,600
New +$204K ﹤0.01% 4774
2025
Q1
Sell
-16,400
Closed -$154K 5105
2024
Q4
$154K Sell
16,400
-9,500
-37% -$98.7K ﹤0.01% 4659
2024
Q3
$277K Buy
+25,900
New +$282K ﹤0.01% 3720
2024
Q1
Sell
-14,400
Closed -$204K 4741
2023
Q4
$204K Sell
14,400
-2,100
-13% -$23.8K ﹤0.01% 3853
2023
Q3
$201K Buy
16,500
+6,500
+65% +$83.8K ﹤0.01% 3745
2023
Q2
$126K Buy
+10,000
New +$119K ﹤0.01% 3702
2022
Q4
Sell
-15,300
Closed -$157K 4315
2022
Q3
$157K Buy
+15,300
New +$170K ﹤0.01% 3736
2021
Q3
Sell
-17,700
Closed -$176K 6462
2021
Q2
$176K Sell
17,700
-30,300
-63% -$296K ﹤0.01% 5102
2021
Q1
$451K Buy
48,000
+31,800
+196% +$492K ﹤0.01% 3856
2020
Q4
$372K Sell
16,200
-6,400
-28% -$131K ﹤0.01% 3500
2020
Q3
$318K Sell
22,600
-16,300
-42% -$238K ﹤0.01% 3327
2020
Q2
$605K Sell
38,900
-400
-1% -$4.87K ﹤0.01% 2531
2020
Q1
$382K Buy
39,300
+1,700
+5% +$16.2K ﹤0.01% 2950
2019
Q4
$358K Sell
37,600
-4,100
-10% -$37.5K ﹤0.01% 3389
2019
Q3
$336K Sell
41,700
-9,300
-18% -$101K ﹤0.01% 3047
2019
Q2
$636K Buy
51,000
+29,200
+134% +$371K ﹤0.01% 2471
2019
Q1
$296K Sell
21,800
-2,000
-8% -$24.4K ﹤0.01% 3368
2018
Q4
$220K Sell
23,800
-64,100
-73% -$705K ﹤0.01% 3593
2018
Q3
$1.06M Sell
87,900
-41,700
-32% -$583K ﹤0.01% 2291
2018
Q2
$1.95M Hold
129,600
﹤0.01% 1616
2018
Q1
$1.95M Buy
129,600
+63,400
+96% +$965K ﹤0.01% 1616
2017
Q4
$953K Sell
66,200
-5,500
-8% -$75.6K ﹤0.01% 2256
2017
Q3
$1.08M Sell
71,700
-800
-1% -$10.6K ﹤0.01% 1846
2017
Q2
$720K Buy
72,500
+26,200
+57% +$211K ﹤0.01% 2062
2017
Q1
$334K Buy
46,300
+4,500
+11% +$28.5K ﹤0.01% 2890
2016
Q4
$208K Sell
41,800
-4,900
-10% -$33.9K ﹤0.01% 3725
2016
Q3
$330K Buy
46,700
+12,600
+37% +$85.1K ﹤0.01% 3098
2016
Q2
$185K Buy
+34,100
New +$238K ﹤0.01% 3333

Other funds holding FOLD

Wolverine Trading's FOLD Position: Q3 2025 in Review

Wolverine Trading reduced its Amicus Therapeutics (FOLD) stake by 57% in Q3 2025, selling an estimated $107K and leaving 11,399 shares worth $90.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5231.

Wolverine Trading first reported a position in FOLD in Q4 2016 and has held it in 21 quarters since. The position peaked at $640K in Q3 2024. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Wolverine Trading held 11,399 shares of Amicus Therapeutics worth $90.5K as of Q3 2025.
  • Wolverine Trading sold 15,039 Amicus Therapeutics shares in Q3 2025, an estimated $107K.
  • Amicus Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5231 holding.
  • Wolverine Trading first reported a position in Amicus Therapeutics in Q4 2016 and has held it in 21 quarters since.
  • Wolverine Trading's Amicus Therapeutics position peaked at $640K in Q3 2024.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.